Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 19, Issue 31, Pages 2919-2936Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026619666191122123855
Keywords
Cilostazol; Mechanism; Clinical application; Anti-platelet aggregation; Antiplatelet drugs; ADP
Categories
Funding
- Programs for Science and Technology Development of Guangxi Province of China [GuiKe attack 1598011-2]
- Guangxi Medical and Health Appropriate Technology Research and Development Project [S201517]
- Natural Science Foundation of Guangxi Province of China [2018GXNSFBA050068]
- Project of Educational Commission of GuangXi Province of China [02601217033C]
- Innovation Project of Guangxi Graduate Education [YCBZ2019044]
Ask authors/readers for more resources
Cilostazol is a unique platelet inhibitor that has been used clinically for more than 20 years. As a phosphodiesterase type III inhibitor, cilostazol is capable of reversible inhibition of platelet aggregation and vasodilation, has antiproliferative effects, and is widely used in the treatment of peripheral arterial disease, cerebrovascular disease, percutaneous coronary intervention, etc. This article briefly reviews the pharmacological mechanisms and clinical application of cilostazol.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
